Artificial Pancreas Device System (APDS) Market- Insights
Administering insulin on a daily basis can be cumbersome for type 1 diabetes (T1D) patients. Devices such as insulin pumps, pens, and jet injectors have made managing diabetes less stressful by replacing painful insulin delivery devices such as needles and syringes. Moreover, organizations such as the Juvenile Diabetes Research Foundation (JDRF) has collaborated with industry players such as Medtronic, Inc., Johnson & Johnson, and Tandem Diabetes Care, Inc. to develop innovative insulin and glucose monitoring systems/devices.
The artificial pancreas device system (APDS) includes an insulin pump, sensor, transmitter, and a receiver. MiniMed 530G by Medtronic, Inc., was the first artificial pancreas device system (APDS) approved by the U.S. FDA. This threshold suspend device system enables temporary suspension of insulin delivery when the glucose level is lower than the threshold level.
Approval and Launch of Novel Technological Advanced Artificial Pancreas Device Systems is Expected to Fuel Market Growth
In June 2017, Medtronic Plc. launched a new hybrid closed-loop system (near-artificial pancreas) for people with type 1 diabetes in the U.S. This newly launched hybrid closed-loop system comprises of Medtronic’s MiniMed 670G insulin pump, fourth-generation sensors, and a control algorithm to determine basal insulin delivery.
This new system was approved by the U.S. FDA in 2016, and it helps to maintain the blood glucose levels within normal range by measuring them every five minutes, and responding automatically by administering or withholding insulin.
Approval and launch of such novel devices is expected to create a lucrative environment for the global artificial pancreas device system (APDS) market growth over the forecast period.
The global artificial pancreas device system (APDS) market size was valued at US$ 123.5 Mn in 2018, and is expected to witness a CAGR of 14.1% during the forecast period (2020 – 2027).
Figure 1. Global Artificial Pancreas Device System (APDS) Market Share (%), By Technology, 2027
Source: Coherent Market Insights Analysis (2019)
Strategic Partnerships and Collaborations Are Expected to Drive the Artificial Pancreas Device System (APDS) Market Growth
In June 2018, Senseonics Holdings, Inc., and Beta Bionics, Inc., entered into a development agreement to integrate glucose data from the Eversense continuous glucose monitoring (CGM) system into the iLet Bionic Pancreas system.
Senseonics Holdings, Inc.’s Eversense CGM system is a long lasting implantable CGM system that continually measures interstitial fluid glucose levels and wirelessly sends the readings to a smartphone application. The Beta Bionics’s, iLet Bionic Pancreas system is a dual-chamber and autonomous infusion pump that mimics biological pancreas by automatically and autonomously adapting insulin and glucagon dosage to meet individual needs of a diabetes patient.
Furthermore, Bigfoot Biomedical acquired Asante’s U.S. FDA approved Snap insulin pump technology in 2015, and in the same year Bigfoot Biomedical signed a development agreement with Dexcom to integrate Dexcom’s CGM with its artificial pancreas device system (APDS). Dexcom collaborated with many other market players such as Insulet Corporation, Animas Corporation, and International Diabetes Closed Loop, in which, these companies would incorporate Dexcom’s CGM in their artificial pancreas device system (APDS).
Such collaborations are expected to expedite entry of new artificial pancreas device systems, and thus expected to drive the artificial pancreas device system (APDS) market growth.
Figure 2. Global Artificial Pancreas Device System (APDS) Market Share (%) Analysis, By Region, 2027
Source: Coherent Market Insights Analysis (2019)
Technical Failure and Side Effects of Artificial Pancreas Device Systems May Reduce Its Adoption and Hinder the Market Growth
In May 2019, the U.S. Food and Drug Administration issued a warning to Do-it-Yourself Artificial Pancreas Systems (DIY APS), following an accidental insulin overdose by a diabetes patient while using the DIY APS. Such technical failures may affect the adoption rate of DIY APS, which, in turn, might hinder growth of the market over the forecast period.
Key players operating in the global artificial pancreas device system (APDS) market include Medtronic Plc., Medtrum Technologies Inc., Tandem Diabetes Care, Inc., Johnson & Johnson, Beta Bionics, Inc., Bigfoot Biomedical, Insulet Corporation, Pancreum, Inc., TypeZero Technologies, Inc., DreaMed Diabetes Ltd, and Inreda Diabetic BV.
Type 1 diabetes patients require multiple doses of insulin in a day. Advancements in research and technology has led to commercialization of easy-to-use insulin delivery systems such as insulin pens, pumps, inhaled insulin, and injectors. Use of syringes to deliver insulin has become obsolete with the introduction of advanced and easy-to-use insulin delivery systems.
Moreover, these systems offer self-administration of insulin. Artificial pancreas system automatically detects glucose level in patient’s blood or plasma, and accordingly administers necessary dosage of insulin. For instance, Medtronic's MiniMed 670G is one such wearable artificial pancreas that automatically monitors glucose levels, and delivers insulin through an insulin pump attached to the device. The artificial pancreas technology includes a transmitter, sensor, and insulin pump. This helps in continuous monitoring of insulin levels in body and manages diabetes at ease.
Continuous research and development of novel artificial pancreas device systems is expected to support the artificial pancreas device system (APDS) market growth over the forecast period.
For instance, in May 2019, Beta Bionics, Inc. and Zealand Pharma started an in-home trial of iLet Bionic Pancreas system, a dual-hormone pump system designed to automatically deliver insulin and dasiglucagon – an experimental form of glucagon designed by Zealand Pharma to be stable in liquid form- based on blood sugar readings from a continuous glucose monitor (CGM).
High prevalence of diabetes type 1 is expected to rise demand for its novel monitoring systems and drive the artificial pancreas device system (APDS) market growth over the forecast period.
For instance, according to the World Health Organization (WHO), number of diabetes patients worldwide increased from 108 million in 1980 to 422 million in 2014. Furthermore, according to the Center for Disease Control and Prevention (CDC), type 1 diabetes accounts for around 5% of the total diagnosed diabetes cases in adults in the U.S.
Key features of the study:
“*” marked represents similar segmentation in other categories in the respective section.